p16 Tumor Suppressor

  • Alexander Kamb
  • Ken McCormack
Part of the Cancer Drug Discovery and Development book series (CDD&D)


p16, a protein named for its migration rate on denaturing gels, is a member of a class of functionally similar proteins called cyclin-dependent kinase inhibitors (CDKI). p16 and its relatives bind to CDKs and inhibit their kinase activity. Because cyclins and CDKs form the core of the cell cycle apparatus, p16 is positioned to directly regulate some of the most basic cell cycle decisions. In eukaryotic cells, the cell cycle is typically described in terms of four component phases: G1, S, G2, and M. Most regulation occurs at the G1—S and G2—M transitions. In higher eukaryotes, the G1 checkpoint is especially important. This is precisely where p16 acts, and its activity is biochemically and functionally linked to other regulators of the G1—S transition, including the wellknown cell cycle regulator (and tumor suppressor protein), Rb.


Germ Line Homozygous Deletion Melanoma Risk Tumor Suppressor Pathway Dysplastic Nevus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Serrano M, Hannon G, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:740–747.CrossRefGoogle Scholar
  2. 2.
    Kamb A, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264:436–440.PubMedCrossRefGoogle Scholar
  3. 3.
    Nobori T, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368:753–756.PubMedCrossRefGoogle Scholar
  4. 4.
    Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61(5):759–767.PubMedCrossRefGoogle Scholar
  5. 5.
    Knudson AJ. Mutation and cancer: statistical study of retinoblastoma. Proc Nall Acad Sci USA 1971; 68:820–823.CrossRefGoogle Scholar
  6. 6.
    Liggett WJ, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998; 16:1197–1206.PubMedGoogle Scholar
  7. 7.
    Kamb A, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994; 8:23–26.PubMedCrossRefGoogle Scholar
  8. 8.
    Spruck CR, et al. p16 Gene in uncultured tumours. Nature 1994; 370:183–184.PubMedCrossRefGoogle Scholar
  9. 9.
    Kamb A, et al. Rates of p16 (MTS1) mutations in primary tumors with 9p loss (response). Science 1994; 265:416.PubMedCrossRefGoogle Scholar
  10. 10.
    Ranade K, et al. Mutations associated with familial melanoma impair p 16INK4 function. Nat Genet 1995; 10:114–116.PubMedCrossRefGoogle Scholar
  11. 11.
    Koh J, et al. Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 1995; 375:506–510.PubMedCrossRefGoogle Scholar
  12. 12.
    Lilischkis R, et al. Cancer-associated mis-sense and deletion mutations impair p 16INK4 CDK inhibitory activity. 66, 1996; 2:249–254.Google Scholar
  13. 13.
    Parry D, Peters G. Temperature-sensitive mutants of p 16CDKN2 associated with familial melanoma. Mol Cell Biol 1996; 16:3844–3852.PubMedGoogle Scholar
  14. 14.
    Merlo A, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p 16/CDKN2/MTS 1 in human cancers. Nat Med 1995; 1:686–692.PubMedCrossRefGoogle Scholar
  15. 15.
    Otterson G, et al. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p 16INK4 protein induction by 5-aza 2′ deoxycytidine. Oncogene 1995; 11:1211–1216.PubMedGoogle Scholar
  16. 16.
    Herman J, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55:4525–4530.PubMedGoogle Scholar
  17. 17.
    Belinsky S, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95:11,891–11,896.CrossRefGoogle Scholar
  18. 18.
    Hussussian C, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8:15–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Elder D, et al. Dysplastic nevus syndrome: a phenotypic association of sporadic cutaneous melanoma. Cancer 1980; 46:1787–1794.PubMedCrossRefGoogle Scholar
  20. 20.
    Piepkorn M. A perspective on the dysplastic nevus controversy. Pathology (Phila) 1994; 2:259–279.Google Scholar
  21. 21.
    Cannon-Albright L, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992; 258:1148–1152.PubMedCrossRefGoogle Scholar
  22. 22.
    Hogg D, et al. Role of the cyclin-dependent kinase inhibitor CDKN2A in familial melanoma. J Cutan Med Surg 1998; 2:172–179.PubMedGoogle Scholar
  23. 23.
    Flores J, et al. Loss of the p16INK4a and p 1 5INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 1996; 56:5023–5032.PubMedGoogle Scholar
  24. 24.
    Liu L, et al. Mutation of the CDKN2A 5′ UTR creates an aberrant initiation codon and predisposes to melanoma. Nat Genet 1999; 21:128–132.PubMedCrossRefGoogle Scholar
  25. 25.
    Soufir N, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998; 7:209–216.PubMedCrossRefGoogle Scholar
  26. 26.
    Cannon-Albright L, et al. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 1994; 54:6041–6044.PubMedGoogle Scholar
  27. 27.
    Flanders T, Foulkes W. Pancreatic adenocarcinoma: epidemiology and genetics. J Med Genet 1996; 33:889–898.PubMedCrossRefGoogle Scholar
  28. 28.
    Park W, et al. Allelic detection at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. Hum Pathol 1998; 29:127–130.PubMedCrossRefGoogle Scholar
  29. 29.
    Zuo L, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996; 12:97–99.PubMedCrossRefGoogle Scholar
  30. 30.
    Wolfel T, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995; 269:1281–1284.PubMedCrossRefGoogle Scholar
  31. 31.
    Nurse P, Masui Y, Hartwell L. Understanding the cell cycle. Nat Med 1998; 4:1103–1106.PubMedCrossRefGoogle Scholar
  32. 32.
    Vogt P, Reed S. In: Vogt P, Reed S, eds., Cyclin Dependent Kinase (CDK) Inhibitors, Berlin, Heidelberg: Springer-Verlag. 1998:139–148.CrossRefGoogle Scholar
  33. 33.
    Russo A, et al. Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 1998; 395:237–243.PubMedCrossRefGoogle Scholar
  34. 34.
    Dynlacht B, et al. Specific regulation of E2F family members by cyclin-dependent kinases. Mol Cell Biol 1997; 17:3867–3875.PubMedGoogle Scholar
  35. 35.
    DeGregori J, Kowalik T, Nevins J. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 1995; 15:4215–4224.PubMedGoogle Scholar
  36. 36.
    Reed J. Mechanisms of apoptosis avoidance in cancer. Curr Opin Oncol 1999; 11:68–75.PubMedCrossRefGoogle Scholar
  37. 37.
    Johnson F, Marciniak R, Guarente L. Telomeres, the nucleolus and aging. Curr Opin Cell Biol 1998; 10:332–338.PubMedCrossRefGoogle Scholar
  38. 38.
    el-Deiry W, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994; 1:1169–1174.Google Scholar
  39. 39.
    Polyak K, et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition in cell cycle arrest. Genes Dey 1994; 8:9–22.CrossRefGoogle Scholar
  40. 40.
    Lukas J, et al. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995; 375:503–506.PubMedCrossRefGoogle Scholar
  41. 41.
    Medema R, et al. Growth suppression by p 16ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 1995; 92:6289–6293.PubMedCrossRefGoogle Scholar
  42. 42.
    Ueki K, et al. CDKN2/p 16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996; 56:150–153.PubMedGoogle Scholar
  43. 43.
    Serrano M, et al. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88:593–602.PubMedCrossRefGoogle Scholar
  44. 44.
    McConnell B, et al. Inhibitors of cyclin-dependent kinases induce features of replicative senescence in early passage human diploid fibroblasts. Curr Biol 1998; 8:351–354.PubMedCrossRefGoogle Scholar
  45. 45.
    Serrano M, et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85:27–37.PubMedCrossRefGoogle Scholar
  46. 46.
    Gruis N, et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995; 10:351–353.PubMedCrossRefGoogle Scholar
  47. 47.
    Stone S, et al. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene. Oncogene 1995; 11:987–991.PubMedGoogle Scholar
  48. 48.
    Stone S, et al. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 1995; 55:2988–2994.PubMedGoogle Scholar
  49. 49.
    Quelle D, et al. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle. Cell 1995; 83:993–1000.PubMedCrossRefGoogle Scholar
  50. 50.
    Kamijo T, et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997; 91:649–659.PubMedCrossRefGoogle Scholar
  51. 51.
    Pomerantz J, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53. Cell 1998; 92:713–723.PubMedCrossRefGoogle Scholar
  52. 52.
    Zhang Y, Xiong Y, Yarbrough W. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92:725–734.PubMedCrossRefGoogle Scholar
  53. 53.
    Kamijo T, et al. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 1998; 95:8292–8297.PubMedCrossRefGoogle Scholar
  54. 54.
    Stott F, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17:5001–5014.PubMedCrossRefGoogle Scholar
  55. 55.
    Bates S, et al. p14 ARF links the tumour suppressors RB and p53. Nature 1998; 395:124–125.PubMedCrossRefGoogle Scholar
  56. 56.
    Palmero I, C Pantoja M. Serrano p19ARF links the tumour suppressor p53 to Ras. Nature 1998; 395:125–126.PubMedCrossRefGoogle Scholar
  57. 57.
    Jiang P, et al. Comparative analysis of Homo sapiens and Mus musculus cyclin-dependent kinase (CDK) inhibitor genes p16 (MTS1) and p15 (MTS2). J Mol Evol 1995; 41:795–802.PubMedCrossRefGoogle Scholar
  58. 58.
    Hannon G, Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 1995; 371:257–261.CrossRefGoogle Scholar
  59. 59.
    Orlow I, et al. Alterations of INK4A and INK4B genes in adult soft tissue sarcomas: effect on survival. J Natl Cancer Inst 1999; 91:73–79.PubMedCrossRefGoogle Scholar
  60. 60.
    Stone S, Dayananth P, Kamb A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res 1996; 56:3199–3202.PubMedGoogle Scholar
  61. 61.
    Foulkes W, et al. The CDKN2A (p16) gene and human cancer. Mol Med 1997; 3:5–20.PubMedGoogle Scholar
  62. 62.
    Barrett M, et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progresion in Barrett’s esophagus. Oncogene 1996. 13:1867–1873.PubMedGoogle Scholar
  63. 63.
    Glendening J, et al. Homozygous loss of the p 161 INK4B gene (and not the p 16INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res 1995; 55:5531–5535.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Alexander Kamb
  • Ken McCormack

There are no affiliations available

Personalised recommendations